American Journal of Hypertension

Age-specific prevalence and factors associated with normal blood pressure among US adults. 2021

Factors associated with not having a healthcare visit in the past year among US adults with hypertension: Data from NHANES 2013-2018. 2021

Together, We've Got This: The US Surgeon General's Call-to-Action on Hypertension Control..  34:893-894. 2021

Is Medication Adherence Predictive of Cardiovascular Outcomes and Blood Pressure Control? The Systolic Blood Pressure Intervention Trial (SPRINT). 2021

Lifestyle behaviors among adults recommended for ambulatory blood pressure monitoring according to the 2017 ACC/AHA blood pressure guideline. 2021

C-Reactive Protein and Incident Hypertension in Black and White Americans in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study.  34:698-706. 2021

Decision Tree-Based classification for maintaining normal blood pressure throughout middle age: findings from the Coronary Artery Risk Development in Young Adults study. 2021

Circadian Control of Sodium and Blood Pressure Regulation. 2021

Paradoxical Increase of 24-Hour Urinary Aldosterone Levels in Obese Patients with Resistant Hypertension on a High Salt Diet.  34:600-608. 2021

N-terminal pro-b-type natriuretic peptide and longitudinal risk of hypertension.  34:476-483. 2021

Twenty-five-year changes in office and ambulatory blood pressure: Results from the coronary artery risk development in young adults (cardia) study.  34:494-503. 2021

Blood Pressure in Childhood and Adolescence.  34:242-249. 2021

Uric Acid Is Not Associated with Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes.  34:64-72. 2021

Using predicted atherosclerotic cardiovascular disease risk for discrimination of awake or nocturnal hypertension.  33:1011-1020. 2020

Association of Obstructive Sleep Apnea With Nighttime Blood Pressure in African Americans: The Jackson Heart Study.  33:949-957. 2020

Reserpine substantially lowers blood pressure in patients with refractory hypertension: A proof-of-concept study.  33:741-747. 2020

Uric acid and hypertension: An update with recommendations.  33:583-594. 2020

Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group.  32:1146-1153. 2019

Ethnic differences in nighttime melatonin and nighttime blood pressure: A study in European Americans and African Americans.  32:968-974. 2019

Health Behaviors, Nocturnal Hypertension, and Non-dipping Blood Pressure: The coronary artery risk development in young adults and jackson Heart study.  32:759-768. 2019

Serum Sodium and Pulse Pressure in SPRINT.  32:649-656. 2019

Blood Pressure Measurement Challenges in Severely Obese Patients.  32:139-140. 2019

Cardioprotective Effects of Paricalcitol Alone and in Combination with FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies.  32:34-44. 2019

West African ancestry and nocturnal blood pressure in African Americans: The Jackson Heart Study.  31:706-714. 2018

Long-term effects of an intensive lifestyle intervention on electrocardiographic criteria for left ventricular hypertrophy: The look AHEAD trial.  31:541-548. 2018

Dietary sodium modifies serum uric acid concentrations in humans.  30:1196-1202. 2017

11-beta dehydrogenase type 2 activity is not reduced in treatment resistant hypertension.  30:518-523. 2017

Cumulative exposure to systolic blood pressure during young adulthood through midlife and the urine albumin-to-creatinine ratio at midlife.  30:502-509. 2017

Psychosocial Correlates of Nocturnal Blood Pressure Dipping in African Americans: The Jackson Heart Study.  29:904-912. 2016

Potential Errors and Omissions Related to the Analysis and Conclusions Reported in Cuspidi C, et al., AJH 2014; 27(2):146-156.  29:780-781. 2016

Prehypertension Is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities Study.  29:568-574. 2016

Clock genes explain a large proportion of phenotypic variance in systolic blood pressure and this control is not modified by environmental temperature.  29:132-140. 2016

Is isolated nocturnal hypertension a reproducible phenotype?.  29:33-38. 2016

Systolic blood pressure control among individuals with type 2 diabetes: A comparative effectiveness analysis of three interventions.  28:995-1009. 2015

Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the coronary artery risk development in young adults (CARDIA) study.  28:640-648. 2015

Is pulse pressure an independent risk factor for incident stroke, REasons for geographic and racial differences in stroke.  28:987-994. 2015

Nocturnal blood pressure in young adults and cognitive function in midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) study.  28:1240-1247. 2015

Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats.  27:720-726. 2014

Prehypertension and incident acute coronary heart disease in the reasons for geographic and racial differences in stroke (Regards) study.  27:245-251. 2014

Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: Challenges and lessons learned.  27:1052-1060. 2014

Hemodynamic and echocardiographic profiles in african american compared with white offspring of hypertensive parents: The HyperGEN study.  27:21-26. 2014

Is pulse pressure an independent risk factor for incident acute coronary heart disease events? the REGARDS study.  27:555-563. 2014

Blood pressure after recent stroke: Baseline findings from the secondary prevention of small subcortical strok.  26:1114-1122. 2013

Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease.  25:789-796. 2012

Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension.  24:708-715. 2011

Moderate waist circumference and hypertension prevalence: The REGARDS study.  24:482-488. 2011

Prehypertension, racial prevalence and its association with risk factors: Analysis of the reasons for geographic and racial differences in stroke (REGARDS) study.  24:194-199. 2011

Adjusting adiposity and body weight measurements for height alters the relationship with blood pressure in children.  23:904-910. 2010

The association of cell cycle checkpoint 2 variants and kidney function: Findings of the family blood pressure program and the atherosclerosis risk in communities study.  22:552-558. 2009

Prenatal programming: Maybe not so hopeless after all?.  22:348. 2009

Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.  18:805-812. 2005

A summary of the effects of antihypertensive medications on measured blood pressure.  18:935-942. 2005

A unifying pathway for essential hypertension.  18:431-440. 2005

Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.  18:287-294. 2005

Genome-wide linkage analyses for age at diagnosis of hypertension and early-onset hypertension in the HyperGEN study.  17:839-844. 2004

Determinants of radial artery pulse wave analysis in asymptomatic individuals.  17:647-653. 2004

Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process.  17:S23-S30. 2004

Genome scan for hypertension in nonobese African Americans: The National Heart, Lung, and Blood Institute Family Blood Pressure Program.  17:834-838. 2004

Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events.  16:265-269. 2003

A Genome-Wide Linkage Analysis Investigating the Determinants of Blood Pressure in Whites and African Americans.  16:151-153. 2003

Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension.  16:51-58. 2003

Excess dietary glucose alters renal function before increasing arterial pressure and inducing insulin resistance.  15:773-779. 2002

Are there meaningful differences in blood pressure control with current antihypertensive agents?.  15:14S-21S. 2002

Obesity: Its time has come.  15:655-656. 2002

Arterial compliance abnormalities in isolated systolic hypertension.  14:1007-1011. 2001

Urinary excretion of vasoactive factors are correlated to sodium excretion.  14:1003-1006. 2001

Elevated potassium intake inhibits neointimal proliferation in the swine coronary artery.  14:879-886. 2001

Cardiovascular effects of estrogen..  14:186S-193S. 2001

The role of the central nervous system in NaCl-sensitive hypertension in spontaneously hypertensive rats..  14:155S-162S. 2001

Blood pressure and arterial compliance in young adults: The Minnesota Children's Blood Pressure Study.  14:200-205. 2001

Factors affecting blood pressure responses to diet: The vanguard study.  13:956-965. 2000

High potassium intake inhibits neointima formation in the rat carotid artery balloon injury model.  13:1014-1020. 2000

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The life study.  13:899-906. 2000

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint..  13:899-906. 2000

Insulin and hypertension in the NHLBI family heart study.  13:240-250. 2000

Newly emerging pharmacologic differences in angiotensin II receptor blockers.  13. 2000

Newly emerging pharmacologic differences in angiotensin II receptor blockers..  13:18S-24S. 2000

Treating multiple-risk hypertensive populations..  12:121S-129S. 1999

Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises.  12:653-664. 1999

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.  12:414-417. 1999

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension..  12:414-417. 1999

Management of the hypertensive patient with coronary artery disease..  12:56S-62S. 1999

Management of the hypertensive patient with coronary artery disease.  12:56S-62S. 1999

Treating multiple-risk hypertensive populations.  12:121-129. 1999

The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study..  11:192S-194S. 1998

Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension..  11:88S-94S. 1998

Case study.  11. 1998

Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension.  11:31-40. 1998

Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension..  11:31-40. 1998

Mibefradil, a T-channel-selective calcium antagonist: Clinical trials in hypertension.  11:88S-94S. 1998

Vascular compliance and cardiovascular disease: A risk factor or a marker?.  10:1175-1189. 1997

Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension..  10:735-742. 1997

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group..  10:705-713. 1997

ALLHAT and calcium channel blockers [3].  10:142-143. 1997

ALLHAT and calcium channel blockers. ALLHAT Research Group..  10:142-143. 1997

Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients.  10:68-76. 1997

Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.  10:735-742. 1997

Erratum: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension (American Journal of Hypertension (July 1997) 10 (735-742)).  10:1081. 1997

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methods.  10:705-713. 1997

Lack of independent relationships between left ventricular mass and cardiovascular reactivity to physical and psychological stress in the coronary artery risk development in young adults (CARDIA) study.  9:915-923. 1996

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group..  9:342-360. 1996

Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).  9:342-360. 1996

Pressor and bradykardie effects of centrally administered relaxin in conscious rats.  8:375-381. 1995

Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats..  5:210-218. 1992

Effects of acute and chronic blockade of neutral endopeptidase with sch 34826 on nacl-sensitive hypertension in spontaneously hypertensive rats.  5:210-218. 1992

Ganglion atrial natriuretic peptide in nacl sensitive spontaneously hypertensive rats.  5:806-810. 1992

The calcium antagonists in the 1990s. An overview..  4:396S-405S. 1991

Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats..  4:449-455. 1991

Altered stores of atrial natriuretic peptide in specific brain nuclei of nacl-sensitive spontaneously hypertensive rats.  4:449-455. 1991

Diagnosis of renovascular hypertension after renal transplantation.  4:724S-730S. 1991

Report of the working party group on determining the radionuclide of choice.  4:747S-748S. 1991

The calcium antagonists in the 1990s an overview.  4:396S-405S. 1991

Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism..  3:179S-188S. 1990

Dietary ca²⁺prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism.  3:179S-188S. 1990

Central mechanisms of hypertension..  2:477-485. 1989

Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats..  2:435-439. 1989

Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension..  2:154-157. 1989

Central mechanisms of hypertension.  2:477-485. 1989

Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats.  2:435-439. 1989

Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension.  2:154-157. 1989